A detailed history of Amundi transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Amundi holds 5,972 shares of RARE stock, worth $282,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,972
Previous 3,938 51.65%
Holding current value
$282,117
Previous $161,000 105.59%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$40.21 - $59.36 $81,787 - $120,738
2,034 Added 51.65%
5,972 $331,000
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $587,943 - $810,896
-15,712 Reduced 79.96%
3,938 $161,000
Q1 2024

May 15, 2024

SELL
$43.02 - $53.69 $3.24 Million - $4.04 Million
-75,288 Reduced 79.3%
19,650 $917,000
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $1.05 Million - $1.63 Million
-33,054 Reduced 25.83%
94,938 $4.54 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $3.36 Million - $4.7 Million
90,062 Added 237.44%
127,992 $5.9 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $26,410 - $34,778
-714 Reduced 1.85%
37,930 $1.52 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $1.09 Million - $1.5 Million
32,286 Added 507.8%
38,644 $1.79 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $254,065 - $420,518
6,358 New
6,358 $258,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.31B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.